| 44.57 Delayed Data As of Nov 15 |  -0.51 / -1.13%Today’s Change | 37.43 Today|||52-Week Range 46.25 | +3.65% Year-to-Date |
| Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges Nov 14 / Zacks.com - Paid Partner Content | Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review Nov 07 / Zacks.com - Paid Partner Content |
| Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q3 Nov 09 / Zacks.com - Paid Partner Content | Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line Nov 06 / Zacks.com - Paid Partner Content |
| Pharma Stock Roundup: LLY, AZN Report Q3 Earnings, PFE Gets FDA Nod for Cancer Drug Nov 09 / Zacks.com - Paid Partner Content | Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates Nov 02 / Zacks.com - Paid Partner Content |
| Alnylam's (ALNY) Q3 Loss Narrower Than Expected, Sales Miss Nov 08 / Zacks.com - Paid Partner Content |
| Previous close | 45.08 |
| Today’s open | 44.09 |
| Day’s range | 43.86 - 44.64 |
| Volume | 1,067,022 |
| Average volume (3 months) | 1,610,390 |
| Market cap | $113.0B |
| Earnings growth (last year) | -15.68% |
| Earnings growth (this year) | -6.48% |
| Earnings growth (next 5 years) | +5.95% |
| Revenue growth (last year) | +5.92% |
| P/E ratio | 30.4 |
| Price/Sales | 2.76 |
| Price/Book | 1.62 |
| Today’s change | Today’s % change | |
|---|---|---|
| LLYEli Lilly and Co | +2.39 | +2.18% |
| AZNAstraZeneca | 0.00 | 0.00% |
| ABTAbbott Laboratories | +1.32 | +1.90% |
| GSKGlaxoSmithKline | -0.48 | -1.17% |
| Next reporting date | February 7, 2019 |
| EPS forecast (this quarter) | $0.64 |
| Annual revenue (last year) | $39.5B |
| Annual profit (last year) | $4.3B |
| Net profit margin | 10.81% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Director Olivier Brandicourt |
Chief Financial Officer & Executive Vice President Jean-Baptiste Chasseloup de Chatillon |
Corporate headquarters Paris, Ile-de-france |
